Entera Bio Ltd. announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. Germano's Age is 65. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman and as a Director, effective February 4, 2026.
Mr. Germano is a pharmaceutical and life sciences executive with more than three decades of leadership experience spanning development, commercialization, and global operations. He held senior leadership roles at Pfizer, including as Group President of Pfizer?s Global Innovative Pharmaceutical Business, where he led the company?s approximately $14 billion innovative medicines portfolio with market-leading medicines and an extensive portfolio of late-stage development candidates in several therapeutic areas. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee at Pfizer from 2013 to February 2016.
Previously, from 2009 through 2013, Mr. Germano served as President and General Manager of Pfizer?s Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets. Additionally, Mr. Germano has served on the board of directors of Precision Biosciences Inc., a clinical stage biotechnology company, since March 2020. In the past five years, Mr. Germano served on the boards of directors of Sage Therapeutics (from 2016 until the company was acquired in 2025), Orbital Therapeutics, a private pre-clinical stage biotechnology company (from March 2025 until the company was acquired in December 2025), Bioverativ Inc. (acquired by Sanofi S.A. in March 2018) and The Medicines Company (acquired by Novartis AG in January 2020).
Mr. Germano received his B.S. in Pharmacy from Albany College of Pharmacy.
